Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyShaji Kumar, Gareth J. Morgan, Paul G. Richardson et al.|Leukemia|2011Cited by 721
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemiaSaroj Vadhan‐Raj, Eric Roeland, Rafat Abonour et al.|Journal of Hematology & Oncology|2017Cited by 88